Northwire Canada EditionSaturday, July 11, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings Neutral

Cannara to Announce Fiscal Q2 2026 Financial Results on April 14, 2026

Cannara Biotech Inc.

Executive Summary
  • Cannara Biotech announced it will release fiscal Q2 2026 financial results on April 14, 2026 at 7:00 AM ET.
  • An earnings webcast featuring CEO Zohar Krivorot and CFO Nicholas Sosiak is scheduled for the same day at 10:00 AM ET with live Q&A; registration link provided.
  • Haywood Securities initiated coverage of Cannara as of April 6, 2026 and issued a research report (details of rating or target price not disclosed in the release).
  • The announcement provides no new operational or financial data beyond the schedule for the upcoming results.
Material Impact
  • The news is primarily procedural: it merely sets the date for the quarterly earnings release, which investors already expect.
  • Haywood’s coverage initiation adds an institutional analyst following, but without a disclosed recommendation or price target its immediate material effect is uncertain and likely incremental.
  • No surprise financial beats/misses, guidance changes, or strategic transactions are reported.
  • Consequently, the announcement is expected to have minimal impact on the share price unless the forthcoming Q2 results deviate significantly from market expectations.
LOVE · Price
Company Overview
  • Cannara Biotech operates two large cultivation facilities in Quebec (> 1.6 million sq ft) with up to 100,000 kg annual production capacity.
  • Flagship project: the Valleyfield processing centre, currently on budget for completion by fiscal year‑end 2026; once operational it will add processing capacity and enable three additional grow zones slated for activation at the start of FY2027.
Read the original news release →

More from Cannara Biotech Inc.